NOVN Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 1.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Novan Share Price & Price History
Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 07/26/2023 12:59 AM ET
Novan Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 6/27/2023 | Machelle Sanders | Director | Sell | 11,553 | $0.41 | $4,736.73 | 25,248 |  |
Novan Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 4/24/2023 | Oak Harbor Wealth Partners LLC | 27,166 | $35K | 0.0% | -48.1% | 0.097% |  |
| 3/15/2023 | B. Riley Wealth Advisors Inc. | 155,000 | $0.23M | 0.0% | +76.5% | 0.728% | |
| 11/14/2022 | Armistice Capital LLC | 2,293,000 | $4.29M | 0.1% | +75.4% | 10.774% | |
| 11/7/2022 | Forum Financial Management LP | 15,000 | $28K | 0.0% | N/A | 0.070% | |
| 9/9/2022 | B. Riley Wealth Management Inc. | 79,150 | $0.18M | 0.0% | +32.7% | 0.372% | |
| 5/11/2022 | Oak Harbor Wealth Partners LLC | 52,366 | $0.21M | 0.1% | +61.8% | 0.273% | |
| 5/11/2022 | GSA Capital Partners LLP | 127,121 | $0.50M | 0.1% | N/A | 0.664% | |
| 5/10/2022 | B. Riley Wealth Management Inc. | 59,650 | $0.24M | 0.0% | +79.9% | 0.312% | |
| 5/10/2022 | First Horizon Advisors Inc. | 15,069 | $59K | 0.0% | N/A | 0.079% | |
| 5/3/2022 | Leo Brokerage LLC | 66,435 | $0.26M | 0.0% | N/A | 0.347% | |
| 2/10/2022 | B. Riley Wealth Management Inc. | 33,150 | $0.14M | 0.0% | +50.7% | 0.176% | |
| 11/15/2021 | GSA Capital Partners LLP | 89,211 | $0.73M | 0.1% | +557.7% | 0.474% | |
| 11/12/2021 | Geode Capital Management LLC | 134,684 | $1.10M | 0.0% | +9.5% | 0.716% | |
| 11/12/2021 | B. Riley Wealth Management Inc. | 22,000 | $0.18M | 0.0% | +14.8% | 0.117% | |
| 11/9/2021 | BlackRock Inc. | 303,017 | $2.47M | 0.0% | -26.9% | 1.611% | |
| 8/16/2021 | State Street Corp | 60,876 | $0.61M | 0.0% | -5.6% | 0.324% | |
Data available starting January 2016
Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina.
Read More on Novan
Today's Range
Now: N/A
50 Day Range
MA: N/A
52 Week Range
Now: N/A
Volume
7,190,000 shs
Average Volume
602,421 shs
Market Capitalization
$2.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
